Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence
Description
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence
Description
The world of CAR/TCR/TIL therapies is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.
In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 236 new CAR/TCR/TIL therapies, over 715 drugs with events, and 5,021 total events spanning 2,374 total drug programs - a clear signal of the accelerating pace and complexity in this space.
Introducing the CAR/TCR/TIL Therapies in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.
The Ultimate Tool for Exploring What Makes This Field So Exciting
6 Game-Changing Benefits for You
With the CAR/TCR/TIL Therapies in Oncology Analytical Tool you will:
Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.
Support & Inspiration at Your Fingertips
Leverage our expertise as your virtual business development team—ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you’ll find actionable insights designed to elevate your work.
A Tool That Grows With You
Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access—complete with near real time updates, new features, pipeline alerts, and dedicated support. When you’re ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology—your comprehensive partner in oncology drug development.
System Requirements
This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.
For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.
In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.
Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.
We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.
Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.
Coverage Breakdown from your CAR/TCR/TIL Therapies in Oncology Analytical Tool
Competitor Overview
Organizations Monitored 870+
Organization Types
1 Gilead Sciences
2 Cellectis
3 MediGene
4 GenScript
5 Carsgen Therapeutics
Top 5 Nations
1 USA
2 China
3 South Korea
4 Germany
5 UK
Pipeline
Total No Drugs 2,370+
Tumor Types 179
Clinical Trials 1,373
Clinical Biomarkers 430
Drugs in Combination Therapies 248
Deals & Alliances
No. Deals (Last 5 Years) 350
BD&L Contacts >1,700
World-Wide Academic Commercial Opportunity Projects 77
Funding & Investors
Funding (Last 5 Years) >600
Top Investors 208
Description
The world of CAR/TCR/TIL therapies is transforming cancer treatment, unlocking new levels of precision, immune activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.
In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 236 new CAR/TCR/TIL therapies, over 715 drugs with events, and 5,021 total events spanning 2,374 total drug programs - a clear signal of the accelerating pace and complexity in this space.
Introducing the CAR/TCR/TIL Therapies in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.
The Ultimate Tool for Exploring What Makes This Field So Exciting
- Highly Specific Tumor Targeting - These therapies use engineered or naturally occurring T cells to precisely recognize and attack cancer cells, minimizing harm to normal tissue.
- Durable and Sometimes Curative Responses - They have produced long-lasting remissions, even in patients with relapsed or treatment-resistant cancers.
- Personalized Treatment Approach - Made from a patient’s own T cells, these therapies are tailored to the individual’s tumor biology for maximum effectiveness.
- Expanding Potential in Solid Tumors - While CAR-T has proven success in blood cancers, TCR and TIL therapies are making promising strides in harder-to-treat solid tumors.
- Platform for Innovation - They offer a flexible foundation for future enhancements, including gene editing, armoring, conditional activation/deactivation, combination therapies, and off-the-shelf options.
6 Game-Changing Benefits for You
With the CAR/TCR/TIL Therapies in Oncology Analytical Tool you will:
Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
- Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
- Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
- Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
- Find the Right Investors - tap into a network of oncology-focused funding partners
- Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)
You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.
Support & Inspiration at Your Fingertips
Leverage our expertise as your virtual business development team—ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you’ll find actionable insights designed to elevate your work.
A Tool That Grows With You
Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access—complete with near real time updates, new features, pipeline alerts, and dedicated support. When you’re ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology—your comprehensive partner in oncology drug development.
System Requirements
- Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
- Internet access
This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.
For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.
In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.
Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.
We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.
Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.
Coverage Breakdown from your CAR/TCR/TIL Therapies in Oncology Analytical Tool
Competitor Overview
Organizations Monitored 870+
Organization Types
- Corporate 684
- Private 446
- Public 182
- Academic 123
- Startup 102
- Cancer Ctr/Hospital 68
- Big Pharma/Biotech 27
1 Gilead Sciences
2 Cellectis
3 MediGene
4 GenScript
5 Carsgen Therapeutics
Top 5 Nations
1 USA
2 China
3 South Korea
4 Germany
5 UK
Pipeline
Total No Drugs 2,370+
- Discovery 440+
- Preclinical 1140+
- Phase 1 510+
- Phase 2 250+
- Phase 3 6
- Pre-registration 2
- Marketed 13
Tumor Types 179
Clinical Trials 1,373
Clinical Biomarkers 430
Drugs in Combination Therapies 248
Deals & Alliances
No. Deals (Last 5 Years) 350
BD&L Contacts >1,700
World-Wide Academic Commercial Opportunity Projects 77
Funding & Investors
Funding (Last 5 Years) >600
Top Investors 208
Table of Contents
- Please Note: For TOC please view description
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
